[go: up one dir, main page]
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 1
2011 1
2012 1
2013 4
2014 6
2015 4
2016 1
2018 1
2019 2
2020 1
2021 2
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand.
Álvarez-Román MT, Shapiro AD, Ragni MV, Palmborg H, Bystrická L, Szamosi J, Casiano S, Chambost H. Álvarez-Román MT, et al. Among authors: szamosi j. Res Pract Thromb Haemost. 2023 Aug 9;7(6):102163. doi: 10.1016/j.rpth.2023.102163. eCollection 2023 Aug. Res Pract Thromb Haemost. 2023. PMID: 37720484 Free PMC article.
Real-world prophylactic usage of recombinant factor IX Fc in Sweden: A report from the Swedish National Registry for bleeding disorders.
Olsson A, Westesson LM, Baghaei F, Holmström M, Olsson E, Magnusson M, Ranta S, Astermark J, Andersson NG, Thanner J, Szamosi J, Daoura L, Sennfält K. Olsson A, et al. Among authors: szamosi j. Haemophilia. 2023 Jan;29(1):377-381. doi: 10.1111/hae.14704. Epub 2022 Dec 5. Haemophilia. 2023. PMID: 36469854 No abstract available.
Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study.
Spiekerkoetter U, Couce ML, Das AM, de Laet C, Dionisi-Vici C, Lund AM, Schiff M, Spada M, Sparve E, Szamosi J, Vara R, Rudebeck M. Spiekerkoetter U, et al. Among authors: szamosi j. Lancet Diabetes Endocrinol. 2021 Jul;9(7):427-435. doi: 10.1016/S2213-8587(21)00092-9. Epub 2021 May 21. Lancet Diabetes Endocrinol. 2021. PMID: 34023005 Clinical Trial.
Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial.
Ranganath LR, Psarelli EE, Arnoux JB, Braconi D, Briggs M, Bröijersén A, Loftus N, Bygott H, Cox TF, Davison AS, Dillon JP, Fisher M, FitzGerald R, Genovese F, Glasova H, Hall AK, Hughes AT, Hughes JH, Imrich R, Jarvis JC, Khedr M, Laan D, Le Quan Sang KH, Luangrath E, Lukáčová O, Milan AM, Mistry A, Mlynáriková V, Norman BP, Olsson B, Rhodes NP, Rovenský J, Rudebeck M, Santucci A, Shweihdi E, Scott C, Sedláková J, Sireau N, Stančík R, Szamosi J, Taylor S, van Kan C, Vinjamuri S, Vrtíková E, Webb C, West E, Záňová E, Zatkova A, Gallagher JA. Ranganath LR, et al. Among authors: szamosi j. Lancet Diabetes Endocrinol. 2020 Sep;8(9):762-772. doi: 10.1016/S2213-8587(20)30228-X. Epub 2020 Aug 18. Lancet Diabetes Endocrinol. 2020. PMID: 32822600 Clinical Trial.
Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.
Oldenburg J, Hay CRM, Jiménez-Yuste V, Peyvandi F, Schved JF, Szamosi J, Winding B, Lethagen S. Oldenburg J, et al. Among authors: szamosi j. BMJ Open. 2019 May 30;9(5):e028012. doi: 10.1136/bmjopen-2018-028012. BMJ Open. 2019. PMID: 31152037 Free PMC article.
27 results